দেশ: আয়ার্লণ্ড
ভাষা: ইংরেজি
সূত্র: HPRA (Health Products Regulatory Authority)
PHYTOMENADIONE
Roche Products Ltd
10 Milligram
Coated Tablets
1983-04-01
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PA0050/051/001 Case No: 2042038 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to ROCHE PRODUCTS LTD 6 FALCON WAY, SHIRE PARK, WELWYN GARDEN CITY, AL7 1TW, UNITED KINGDOM an authorisation, subject to the provisions of the said Regulations, in respect of the product KONAKION 10MG COATED TABLETS The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 01/04/2008. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 10/04/2008_ _CRN 2042038_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Konakion 10 mg Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each Konakion Tablet contains 10mg Phytomenadione (vitamin K 1 ). Excipients: Each tablet contains 530.5mg sucrose, 75mg glucose and between 37.6mg and 41.6mg lactose monohydrate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Coated tablet. Round, off-white, sugar-coated tablets. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Konakion is indicated in the treatment of haemorrhage or threatened haemorrhage associated with a low blood level of prothrombin or factor VII. The main indications are: As an antidote to a সম্পূর্ণ নথি পড়ুন